Whole-exome sequencing in relapsing chronic lymphocytic leukemia : clinical impact of recurrent RPS 15 mutations

Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations Viktor Ljungström,* Diego Cortese,* Emma Young, Tatjana Pandzic, Larry Mansouri, Karla Plevova, Stavroula Ntoufa, Panagiotis Baliakas, Ruth Clifford, Lesley-Ann Sutton, Stuart J. Blakemore, Niki Stavroyianni, Andreas Agathangelidis, Davide Rossi, Martin Höglund, Jana Kotaskova, Gunnar Juliusson, Chrysoula Belessi, Nicholas Chiorazzi, Panagiotis Panagiotidis, Anton W. Langerak, Karin E. Smedby, David Oscier, Gianluca Gaidano, Anna Schuh, Frederic Davi, Christiane Pott, Jonathan C. Strefford, Livio Trentin, Sarka Pospisilova, Paolo Ghia, Kostas Stamatopoulos, Tobias Sjöblom, and Richard Rosenquist Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala, Sweden; Central European Institute of Technology, Masaryk University and University Hospital Brno, Brno, Czech Republic; Institute of Applied Biosciences, Center for Research and Technology Hellas, Thessaloniki, Greece; Oxford National Institutes of Health Research Biomedical Research Centre, University of Oxford, Oxford, United Kingdom; Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, United Kingdom; Hematology Department and Hematopoietic Cell Transplantation Unit, G. Papanicolaou Hospital, Thessaloniki, Greece; Università Vita-Salute San Raffaele and Division of Experimental Oncology and Department of Onco-Hematology, Istituto di Ricovero e Cura a Carattere Scientifico San Raffaele Scientific Institute, Milan, Italy; Division of Hematology, Department of Translational Medicine, Amedeo Avogadro University of Eastern Piedmont, Novara, Italy; Department of Medical Sciences, Section of Hematology, Uppsala University, Uppsala, Sweden; Department of Laboratory Medicine, Stem Cell Center, Lund University, Lund, Sweden; Hematology Department, General Hospital of Nikea, Piraeus, Greece; Karches Center for Chronic Lymphocytic Leukemia Research, The Feinstein Institute for Medical Research, Manhasset, New York; First Department of Propaedeutic Medicine, School of Medicine, University of Athens, Athens, Greece; Department of Immunology, Laboratory for Medical Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands; Department of Medicine Solna, Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden; Department of Haematology, Royal Bournemouth Hospital, Bournemouth, United Kingdom; Laboratory of Hematology and Universite Pierre et Marie Curie, Hopital Pitie-Salpetriere, Paris, France; Second Medical Department, University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany; and Department of Medicine, Hematology and Clinical Immunology Branch, Padua University School of Medicine, Padua, Italy

[1]  A. Pettitt,et al.  Presence of multiple recurrent mutations confers poor trial outcome of relapsed/refractory CLL. , 2015, Blood.

[2]  Martin A. Nowak,et al.  Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.

[3]  Viktor Ljungström,et al.  Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting , 2015, Haematologica.

[4]  B. Sander,et al.  Functional loss of IB leads to NF-B deregulation in aggressive chronic lymphocytic leukemia , 2015 .

[5]  R. Rosenquist,et al.  Deciphering the molecular landscape in chronic lymphocytic leukemia: time frame of disease evolution , 2015, Haematologica.

[6]  Š. Pospíšilová,et al.  Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia , 2014, Leukemia.

[7]  E. Campo,et al.  Recurrent mutations refine prognosis in chronic lymphocytic leukemia , 2014, Leukemia.

[8]  Satoru Miyano,et al.  Acquired initiating mutations in early hematopoietic cells of CLL patients. , 2014, Cancer discovery.

[9]  L. Pasqualucci,et al.  Genetic lesions associated with chronic lymphocytic leukemia chemo-refractoriness. , 2014, Blood.

[10]  Raul Rabadan,et al.  Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. , 2013, Blood.

[11]  Medical Faculty,et al.  High-Resolution Genomic Profiling of Chronic Lymphocytic Leukemia Reveals New Recurrent Genomic Alterations , 2014 .

[12]  B. Giusti,et al.  EXCAVATOR: detecting copy number variants from whole-exome sequencing data , 2013, Genome Biology.

[13]  X. Jacq,et al.  Ribosomal Proteins RPL37, RPS15 and RPS20 Regulate the Mdm2-p53-MdmX Network , 2013, PloS one.

[14]  Francesco Bertoni,et al.  MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia , 2013, Leukemia & lymphoma.

[15]  Carlos Caldas,et al.  The implications of clonal genome evolution for cancer medicine. , 2013, The New England journal of medicine.

[16]  D. Catovsky,et al.  The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. , 2013, Blood.

[17]  Stein Aerts,et al.  Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia , 2012, Nature Genetics.

[18]  A. McKenna,et al.  Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia , 2012, Cell.

[19]  Jenny Taylor,et al.  Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. , 2012, Blood.

[20]  A. Look,et al.  Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. , 2012, Blood.

[21]  Christopher A. Miller,et al.  VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.

[22]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[23]  E. Giné,et al.  Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia , 2011, Nature Genetics.

[24]  L. Pasqualucci,et al.  Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. , 2011, Blood.

[25]  A. Sivachenko,et al.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. , 2011, The New England journal of medicine.

[26]  Juliane C. Dohm,et al.  Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia , 2011, Nature.

[27]  L. Pasqualucci,et al.  Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation , 2011, The Journal of experimental medicine.

[28]  M. DePristo,et al.  A framework for variation discovery and genotyping using next-generation DNA sequencing data , 2011, Nature Genetics.

[29]  A. Berrebi,et al.  Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial , 2010, The Lancet.

[30]  Richard Durbin,et al.  Fast and accurate long-read alignment with Burrows–Wheeler transform , 2010, Bioinform..

[31]  Michael Hallek,et al.  Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. , 2008, Blood.

[32]  P. Loehrer.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2008 .

[33]  T Hamblin,et al.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial , 2007, The Lancet.

[34]  K. Do,et al.  Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.